A pharmaceutical company near Sandbach has announced the expansion of a partnership which will enable them to manufacture climate-friendly inhalers.

Bespak, the specialist Holmes Chapel inhalation company, and The Chiesi Group, an international research focused biopharmaceutical company today (Wednesday) announced an expansion of their long-standing partnership.

This will enable Bespak in London Road to increase pressurised metered dose inhaler (pMDI) manufacturing to support the next phase of a Carbon Minimal Inhaler (CMI) program. 

A spokesperson said: "Building on years of collaboration, the agreement reflects a shared long-term vision: delivering lower carbon inhaled therapies through CMIs at scale, without compromising clinical choice or continuity of care for patients. 

"Both companies are committed to addressing climate change through measurable, science-based action. Chiesi's ambition to reach Net Zero targets by 2035, and Bespak's validated decarbonization roadmap, underpin a partnership grounded in shared sustainability principles. 

Maria Paola Chiesi, Chiesi Group Vice Chair, said: "The partnership with Bespak reinforces our efforts to reduce emissions across the value chain, while protecting access, quality and trust. Climate action and patient care must continue to advance hand in hand." 

To meet the needs of patients and reduce impact on the environment, Chiesi is working to be the only company to offer a portfolio of extrafine formulation Carbon Minimal Inhalers, including both dry powder inhalers (DPIs) and next generation propellant pMDIs.

Positioned in the North West of England's inhalation R&D and manufacturing cluster, the site contributes high value skills, advanced technical expertise and long-term investment in sustainable inhaler manufacturing, for the benefit of patients and healthcare systems worldwide. 

advertisement

Giuseppe Accogli, Chiesi Group CEO, added: "This agreement strengthens an already established partnership with Bespak, and is a concrete example of how we translate our ambition into action. "

Chris Hirst, Bespak CEO, said: "Our collaboration with Chiesi has grown over time around a shared commitment to patient safety, technical excellence and sustainability.

"By deepening this partnership, we are accelerating the transition to low carbon pMDIs and reinforcing the UK's role as a centre of excellence for sustainable inhalation manufacturing. 

"This is a position being recognised by the wider industry, leading to our Holmes Chapel site being selected as a key source of supply by leading brand owners like Chiesi, cementing our role as a strategic supply chain partner for the next generation propellant inhalers and innovative nasally-delivered therapies." 

Would you like to know more about Sandbach?

Free from clickbait, pop-up ads and unwanted surveys, Sandbach Nub News is a quality online newspaper for our town.

Please consider following Sandbach Nub News on Facebook  or X (Twitter)

We also have a weekly newsletter with the TOP FIVE stories of the week - sign up here

advertisement